Can Wegovy Increase Blood Pressure — or Does It Lower It?

What the STEP trials actually found about blood pressure

The most direct answer to whether semaglutide increases blood pressure comes from the STEP clinical programme, which enrolled thousands of adults with obesity across multiple countries. In STEP 1, participants taking the 2.4 mg maintenance dose experienced an average reduction in systolic blood pressure of around 6 mmHg over 68 weeks, compared with approximately 1 mmHg in the placebo group. Diastolic pressure showed smaller but similar directional changes.

This is broadly consistent with what you would expect from substantial weight loss: adipose tissue around the blood vessels contributes to vascular resistance, and as that tissue reduces, pressure tends to ease. The NHS medicines information for semaglutide does not list raised blood pressure as a recognised common side effect, which reflects the overall direction of the trial evidence.

For people whose blood pressure was already elevated at baseline, the reductions in the STEP programme were often more pronounced. That is not a guaranteed outcome for any individual, but it is the pattern the data show. If you are wondering whether does semaglutide increase blood pressure is even the right question, the better framing may be: for whom, at what stage, and under what circumstances?

When blood pressure might rise on Wegovy, and why

A minority of people do report higher readings, particularly in the first few weeks. There are a few plausible mechanisms worth knowing about, even though none of them are fully established for semaglutide at the clinical doses used in Wegovy.

First, heart rate. GLP-1 receptor agonists are associated with a modest increase in resting heart rate, typically around 1–4 beats per minute in trials. An elevated heart rate does not necessarily mean elevated blood pressure, but the two are linked. If your heart is working slightly harder at rest, readings can be borderline higher early on, before weight-loss effects take over.

Second, the slow titration itself matters. The Wegovy schedule starts at 0.25 mg and progresses in stages, the full titration schedule illustrates how gradual that progression is designed to be. Moving through doses carefully helps manage side effects, including any early cardiovascular adjustment. If you have been wondering when a dose increase is appropriate, that pacing is part of the safety rationale.

Third, dehydration. Nausea, particularly in the early weeks, can reduce fluid intake and cause temporary blood pressure fluctuations in either direction. Keeping well hydrated is a practical, not trivial, part of managing early treatment.

What this means if you are already managing hypertension

This is where the evidence gets most clinically relevant, and if this describes your situation, it is completely understandable to feel uncertain about starting a new medicine when blood pressure is already a concern.

The reassuring finding from the STEP data is that people with hypertension at baseline tended to see the most improvement. However, that improvement can come quickly enough that existing antihypertensive medications may eventually need adjusting. A prescriber who is told about all your current medications before treatment starts is the person best placed to plan for that. This is not a reason to avoid Wegovy if you are otherwise eligible; it is a reason to be monitored.

The NHS England guidance on weight-management injections specifically advises telling your clinical team about all medicines you are taking, including blood pressure drugs, before starting treatment. That is standard practice, and at our pharmacy, your prescriber reviews this detail as part of the consultation.

Wegovy is a prescription-only medicine, and questions about your specific cardiovascular situation, including hypertension, blood pressure medication, or a history of cardiovascular events, are exactly what the clinical assessment is there to address. You can find out more about how the Wegovy dosing range works and how individual suitability is assessed before any prescription is issued.

The broader cardiovascular picture for semaglutide

It is worth stepping back to the wider evidence base. Semaglutide (Wegovy) holds a UK licence for reducing the risk of major cardiovascular events (heart attack, stroke and cardiovascular death) in adults with obesity and established cardiovascular disease. That authorisation was granted on the basis of large-scale outcome data, not just surrogate measures like blood pressure readings. Blood pressure reduction is part of the story; it is not the only cardiovascular mechanism in play.

For people thinking about the overall heart-health implications of Wegovy, the trial programme offers some of the most robust long-term data available for any weight-loss medicine. The question of whether semaglutide increases blood pressure in a clinically meaningful way has a fairly clear answer at the population level: the predominant effect runs in the opposite direction, though you can read more about how Wegovy increases are managed over the course of treatment. Individual responses vary, monitoring matters, and prescriber oversight is what makes that monitoring possible.

If you want to explore whether Wegovy is right for your situation, pricing and what is included in a private prescription are covered separately. The right starting point is a conversation with a clinician. Speak to our prescribers to have your health history reviewed and your questions answered directly.